Progress Toward Measles Elimination in India: Epidemiological Trends, Gaps, and Policy Implications (2000–2025)
International Journal of Drug Delivery Technology · 14.04.2026 · 16 (11s)
DOI: 10.25258/ijddt.16.11s.64 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Drug Delivery Technology, online erschienen am 14.04.2026. Verfasst von Subhajit Chakraborty und 1 weiteren Autor:innen.
Abstract (Originalsprache)
Background
India adopted measles elimination as a national goal in 2019 (revised target from 2023 to 2025/2027– 2028), aligning with WHO South-East Asia Region (SEARO) benchmarks. This systematic review assesses progress over 25 years amid vaccination scale-up, MR campaign implementation, and COVID-19 disruptions.
Methods
PRISMA 2020-compliant systematic analysis of measles epidemiology, vaccination coverage, and surveillance data from January 2000 to December 2025. Literature searched via PubMed, Scopus, Web of Science, EMBASE, and grey literature (WHO, UNICEF, MoHFW, SEARO, IDSP, GBD 2023). Inclusion criteria: national/state-level measles data; MCV1/MCV2 coverage estimates; case surveillance; outbreak reports. Quality assessed using JBI checklist.
Results
Measles incidence declined 83% from 628.8 per million (2013 peak) to 52.0 per million (2020), reaching ~40 per million (2024). MCV1 coverage increased from 68% (2000) to 91% (2023), while MCV2 increased from 0% (2012) to 82% (2021). However, only 94% of states achieved ≥95% MCV1 coverage, and ≥94% MCV2 coverage remains elusive nationally. COVID-19 caused a 60% vaccination decline in April 2020, with incomplete recovery through 2023. District-level analysis revealed persistent coverage disparities (60–95%), with North-East and lowincome states lagging. Laboratory network expansion (13 to 27 laboratories, 2011–2021) improved surveillance, though non-measles/non-rubella discard rates remain suboptimal. Case fatality rate fluctuated (0.13% in 2014 to 3.3% in 2020), indicating resurgence risk.
Conclusion
India has achieved substantial measles mortality reduction but faces structural barriers to elimination. District-level MCV2 bottleneck, surveillance sensitivity gaps, immunity gaps from COVID-19 disruptions, and socioeconomic disparities persist. Realistic elimination feasibility: 2027–2028 (conditional on intensified districtfocused strategies). This review identifies 8–10 prioritized policy recommendations including zero-dose registries, digital immunization tracking, and school-entry MCV2 mandates.
Zitieren
APA
Chakraborty, S., & Lenka, D. A. K. (2026). Progress Toward Measles Elimination in India: Epidemiological Trends, Gaps, and Policy Implications (2000–2025). International Journal of Drug Delivery Technology, 16(11s). https://doi.org/10.25258/ijddt.16.11s.64
Vancouver
Chakraborty S, Lenka DAK. Progress Toward Measles Elimination in India: Epidemiological Trends, Gaps, and Policy Implications (2000–2025). International Journal of Drug Delivery Technology. 2026;16(11s). doi:10.25258/ijddt.16.11s.64
BibTeX
@article{Chakraborty2026,
author = {Chakraborty, Subhajit and Lenka, Dr Ajit Kumar},
title = {Progress Toward Measles Elimination in India: Epidemiological Trends, Gaps, and Policy Implications (2000–2025)},
journal = {International Journal of Drug Delivery Technology},
year = {2026},
volume = {16},
number = {11s},
doi = {10.25258/ijddt.16.11s.64}
}
EUVIMED